AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Effectiveness and Health Economics of Endoluminal Treatment of Arteriovenous Graft Fistula.

Recruitingn/aAges 18 Years - 80 YearsAllRenJi Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study is a prospective, single-center real-world research, aiming to understand the clinical intervention effects and health economics value of various endovascular treatment methods for arteriovenous graft fistula failure in the real world. The target lesion is defined as the inflow tract (artery, anastomosis, bend), middle segment, and outflow vein of the dialysis pathway. The study will recruit 240 patients with arteriovenous graft fistula failure at a single center from September 2023 to December 2024. Depending on different treatment methods, patients will be divided into several subgroups, such as the simple balloon dilation group, drug balloon group, stent implantation group, etc. As this is a real-world study, the main observations will be the technical success rate of various endovascular treatment methods, major adverse events during the perioperative period, and the sympt

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Patients aged 18 to 80 years undergoing hemodialysis; 2. Patients with arteriovenous graft fistula unable to complete hemodialysis; 3. The guidewire must pass through the stenosis of the lesion side's graft fistula and further undergo endovascular treatment to be eligible for inclusion. This study does not limit the form of guidewire passing through the target lesion; 4. Patients who have successfully undergone endovascular treatment again after the initial target lesion opening failure are still eligible for inclusion; 5. Subjects and their legal representatives understand the purpose of the study, voluntarily participate, and sign informed consent forms, willing to undergo follow-up at specific time points in this trial. Exclusion Criteria: 1. Planned kidney transplant or conversion to peritoneal dialysis 2. Women who are pregnant,breastfeeding or planning to become pregnant during the study period 3. Recent (within 30 days) or planned surgical procedure for haemodialysis access 4. Allergy or contraindication to heparin, contrast media, antiplatelet drugs 5. Patients who have participated in a clinical trial of a drug or other medical device that interferes with this clinical trial within the last 3 months. 6. Patients with a history of coagulation disorders or other haematological disorders 7. Patients with other conditions that may make the trial difficult or significantly shorten the patient's life expectancy (\<2 years), e.g.tumours,severe liver disease,cardiac insufficiency,etc.,or patients with a life expectancy of less than 6 months. 8. Patients unable or unwilling to participate in this trial
๐Ÿ’Š

What it tests

  • Endovascular therapy
๐Ÿ“

Where

1 site
Renji Hospital
Shanghai, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy